乐虎lehu国际官网

Clinical study of recombinant human epidermal growth factor solution combined with compound polymyxin B ointment for residual wounds in the late stage of burns

2025-09-12 0

Abstract : Objective To observe the clinical effect of recombinant human epidermal growth factor topical solution combined with Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) for residual wound healing in the late stage of burns. Methods 35 patients with skin burns were selected, with a total of 60 wounds. They were randomly divided into two groups: the treatment group, 18 cases, with 35 wounds; the control group, 17 cases with 25 wounds. The treatment group applied recombinant human epidermal growth factor topical solution combined with Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment). After 1-2 courses of treatment, the bacterial clearance rate and healing status of the wounds in the two groups were observed. Results: The total effective rate of the treatment group was 92.5%, which was significantly higher than the 53.5% of the control group (P<0.01); the bacterial clearance of the wound. There were 13 cases of bacterial infection in the control group, 10 cases of bacterial infection and 8 cases of bacterial infection in the treatment group. .Clear 3 cases. The healing time of the treatment group (14.7±3.1) days and the control group (24.6±7.6) days was significantly different (P<0.01). Conclusion Recombinant human epidermal growth factor topical solution combined with Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) effectively controls infection. It improves the quality of healing and shortens the healing time.


 Mei Haoxing. Clinical study of recombinant human epidermal growth factor solution combined with compound polymyxin B ointment for residual wounds in the late stage of burns[J]. Global Chinese Medicine, 2015, 8(S2):190.





To Top